Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients post-Allo-HSCT: a phase I trial

Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients post-Allo-HSCT: a phase I trial

Abstract Relapse remains a major challenge for high-risk acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). In our first-in-human Phase I trial (ChiCTR-1900022795), we have demonstrated that third-party donor-derived double-negative T cell...

Full description

Saved in:
Bibliographic Details
Main Authors: Guangyu Sun, Xingchi Chen, Tianzhong Pan, Kaidi Song, Haicun Xie, Meijuan Tu, Xiang Wan, Wen Yao, Yaxin Cheng, Ziwei Zhou, Dongyao Wang, Yongsheng Han, Baolin Tang, Liming Yang, Xiaoyu Zhu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Experimental Hematology & Oncology
Subjects:
Double negative T cell
Acute myeloid leukemia
Allogeneic hematopoietic stem cell transplantation
Relapse
Adoptive cellular therapy
Immune modulator
Online Access:https://doi.org/10.1186/s40164-025-00680-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40164-025-00680-1

Similar Items